When given at a time that the FDA-approved clot-busting drug therapy tPA (tissue plasminogen activator) is ineffective, the combination of tPA and an experimental compound called 3K3A-APC reduces brain damage, eliminates brain hemorrhaging and improves motor skills in rodents afflicted by stroke.